Clinical Trials | December 29, 2025
Quantum BioPharma completes key toxicity studies for Lucid-MS, paving way for Phase 2 MS trial
Lucid-MS represents a potential breakthrough in the treatment of multiple sclerosis
Lucid-MS represents a potential breakthrough in the treatment of multiple sclerosis
For 2026 onwards, CPHI and PMEC India are evolving into two distinct, specialized shows
Indian Pharmacopoeia is now recognised in 19 countries, reflecting growing international confidence in India’s regulatory and scientific capabilities
CLE, a common form of lupus erythematosus, primarily causes diverse skin lesions
The new single-use commercial facility will be among India’s largest, featuring advanced technologies to produce high-quality biologics and specialty pharmaceuticals
The opening of our 1000th pharmacy in Karnataka marks an important step
These observations are procedural in nature and the company does not anticipate any impact on supply of its commercial products
U.S. and Canada transaction supports continued access to RADICAVA for people living with ALS
Under the terms of the deal, AstraZeneca gains exclusive rights to JAB-23E73 outside of mainland China
Shonan iPark was chosen for its globally connected life-science ecosystem, which unites pharmaceutical firms, next-generation medicine developers, AI and digital health innovators, venture capital, and academia
Subscribe To Our Newsletter & Stay Updated
